| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 2.22 | 28.3% | 6.3% |
| Total Income | 2.22 | 28.3% | 6.3% |
| Expenditure | 4.91 | 6.0% | 25.9% |
| PBT | 0.47 | 103.8% | 80.1% |
| Net Profit | 0.47 | 103.8% | 80.1% |
| OPM | — | ||
| NPM | 21.11% | 78.51pp | |
| EPS | 0.56 | 100.9% | 67.8% |
Nuwellis Reports Q3 2025 Results: Revenue $2.2 Million
04 May 2026 · 4 May, 7:27 am
Summary
Nuwellis, Inc. reported its third quarter 2025 financial results, with total revenue of $2.2 million, down 6% year-over-year but up 29% sequentially. Pro-forma revenue grew approximately 7% year-over-year. The company achieved growth in circuit sales across all customer categories and launched new products in the U.S. market. Nuwellis is focusing on U.S. market growth and has initiated a manufacturing transition and exit of international operations.
Key Highlights
- 1
Total revenue was $2.2 million, a decrease of 6% year-over-year, but an increase of 29% sequentially.
- 2
On a pro-forma basis, revenue grew approximately 7% year-over-year, excluding one-time SeaStar medical revenue and a decrease in international revenue.
- 3
All customer categories achieved year-over-year growth in circuit sales.
- 4
The company launched a new 24-hour circuit and dual-lumen extended-length catheter in the U.S.
- 5
Pediatric product development accelerated through an NIH-funded collaboration.
- 6
The company initiated a manufacturing transition to KDI Precision Manufacturing and exited international operations.
- 7
Nuwellis raised $1.9 million through its ATM facility during the quarter.
Management Comments
John Erb
“Our third quarter results reflect disciplined execution and meaningful progress toward building a more focused, U.S.-driven business. We continue to strengthen our leadership in precision fluid management across critical care, pediatrics, and hospital-based outpatient therapy. With the launch of our new 24-hour circuit and successful early hospital-based outpatient treatments, we are expanding how and where Aquadex therapy can be delivered to improve patient outcomes.”
Informational and educational content only. Not investment advice.